Table 1.
Ongoing clinical trials of new drugs against retinal and choroidal angiogenesis
| NCT number | Drug | Target/mechanism | Phase | Conditions |
|---|---|---|---|---|
| NCT02543229 | OPT-302 | VEGF-C VEGF-D | 1 | Eye diseases, macular degeneration, retinal diseases, retinal degeneration, pathologic neovascularization |
| NCT02591914 | E10030 (Fovista) | PDGF | 1 | Neovascular age-related macular degeneration |
| NCT01940887 | 3 | |||
| NCT02348359 | X-82 | VEGF | 2 | Age-related macular degeneration, macular degeneration, exudative age-related macular degeneration, age-related macular degeneration, eye diseases, retinal degeneration, retinal diseases |
| PDGF | ||||
| NCT02699450 | RO6867461 | VEGF | 2 | Diabetic macular edema |
| ANG-2 | ||||
| NCT02530918 | DS-7080ª | Robo-4 | 1 | Neovascular age-related macular degeneration |
| NCT02727881 | OHR-102 (Squalamine lactate) | VEGF | 3 | Age-related macular degeneration |
| PDGF | ||||
| bFGF | ||||
| NCT02857517 | Conbercept | VEGF-A | 2 | Proliferative diabetic retinopathy, idiopathic choroidal neovascularization, retinal vein occlusion, polypoidal choroidal vasculopathy, branch retinal vein occlusion, macular edema, neovascular glaucoma, age-related macular degeneration, pathological myopia, diabetic macular edema, wet age-related macular degeneration |
| NCT02911311 | VEGF-B | NP | ||
| NCT03108352 | VEGF-C | 3 | ||
| NCT03159884 | PlGF | 4 | ||
| NCT03154892 | NP | |||
| NCT03128463 | NP | |||
| NCT02194634 | 3 | |||
| NCT03054818 | NP | |||
| NCT01024998 | AAV2-sFLT01 | Vector to neutralizes VEGF | 1 | Macular degeneration, age-related maculopathies, age-related maculopathy, retinal degeneration, retinal neovascularization, gene therapy, eye diseases |
| NCT02307682 | RTH258 (Brolucizumab) | VEGF-A | 3 | Neovascular age-related macular degeneration |
| NCT02434328 | ||||
| NCT02713204 | REGN910 (Nesvacumab) | Inactivates the Tie2 receptor ligand ANG-2 | 2 | Neovascular age-related macular degeneration |
| NCT02555306 | DE-122 | Endoglin | 2 | Age-related macular degeneration |
| NCT02914639 | SF0166 Topical Ophthalmic Solution | Integrin αvβ3 | 2 | Age-related macular degeneration |
| NCT02462928 | Abicipar pegol | VEGF | 3 | Macular degeneration |
| PDGF | ||||
| NCT02867735 | LKA651 | Erythropoietin | 1 | Macular edema, diabetic macular edema, neovascular age-related macular degeneration, retinal vein occlusions |
| NCT02613559 | TK001 (Sevacizumab) | VEGF | 1 | Neovascular age-related macular degeneration |
| NCT02484690 | RG7716 | VEGF | 2 | Macular degeneration, choroidal neovascularization |
| ANG-2 | ||||
| NCT03066258 | RGX-314 gene therapy | VEGF | 1 | Neovascular age-related macular degeneration, wet age-related macular degeneration |
From http://www.clinicaltrials.gov. Accessed June 11, 2017. Searched terms: ocular angiogenesis, age-related macular degeneration, retinal neovascularization, choroidal neovascularization; Recruitment: “closed studies/active, not recruiting” AND “open studies/recruiting”. Abbreviations: ANG-2, angiopoietin-2; bFGF, Basic fibroblast growth factor; NCT, National Clinical Trial; PlGF, Placental growth factor; Robo-4, Roundabout Guidance Receptor-4; NP, not provided; VEGF, vascular endothelial growth factor